Abstracts

95 EFFICACY, DAMAGE ACCRUAL AND PREDICTORS OF RESPONSE TO BELIMUMAB IN ACTIVE SLE PATIENTS: A LARGE ITALIAN MULTICENTER PROSPECTIVE STUDY

1'M Larosa*, 1L Laccarino, 1M Zen, 1M Gatto, 1E Enri, 1F Conti, 1M Mosca, 1P.L. Meroni, 1M Grivon, 1S De Vita, 1R De Angelis, 1C Salvarani, 1R Geri, 1A Tincani, 1A Doria, 1Università degli Studi di Padova – Azienda Ospedaliera, Department of Medicine-DIMED-Division of Rheumatology, Padova, Italy, 2University of Florence, Interdisciplinary Internal Medicine-Centre for Autoimmune Systemic Diseases- Behyet Centre and Lupus Clinic, Florence, Italy, 3Sapienza University, Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Rome, Italy, 4University of Pisa, Department of Clinical and Experimental Medicine-Rheumatology Unit, Pisa, Italy, 5IRCCS Istituto-Auxologico Italiano, Experimental Laboratory of Immunological and Rheumatologic Researches, Milan, Italy, 6University of Ferrara, Rheumatology Unit, Department of Medical Sciences, Ferrara, Italy, 7Università degli Studi di Padova – Azienda Ospedaliera-IRCCS di Reggio Emilia, Rheumatology Unit, Department of Internal Medicine, Reggio Emilia, Italy, 8University of Perugia, Rheumatology Unit, Department of Medicine, Perugia, Italy, 9Azienda Ospedaliera-Università degli Studi di Brescia - Azienda Ospedaliera-Università degli Studi di Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy.

Conclusions Belimumab seems to be effective and to reduce damage accrual in SLE patients in clinical practice setting. Patients with arthritis and high disease activity were the best responders to belimumab.

96 URINARY BIOMARKER RELATED WITH TUBULAR INFLAMMATION IN LUPUS NEPHRITIS

1E Ji Lee, 2S Hong, 3E Chang, 4B Yoo, 5CK Lee, 6YG Kim, 1University of Ulsan College of Medicine-Asan Medical Centre, Department of Rheumatology, Seoul, Republic of Korea, 2University of Ulsan College of Medicine-Asan Medical Centre, Department of Biomedical Sciences-Cell Dysfunction Research Centre and BMIT, Seoul, Republic of Korea.

Conclusions Urinary levels of IGBP1 were significantly higher in LN patients than in SLE patients without nephritis and healthy individuals. Among the disease-related variables, SLEDAI scores, anti-dsDNA, and C3 were correlated with the levels of urinary IGBP1. Further, urinary IGBP1 levels represented a positive association with activity index score in renal pathology. IGBP1 was stained mainly in tubules, especially in class III, IV and V. In microarray analysis, IL-7 receptor was closely related with IGBP1 down-regulation. Therefore, urinary IGBP1 might be a valuable marker for determining the activity of LN.